Navigation Links
Elekta Announces Monaco 5.0 -- Comprehensive Radiation Treatment Planning Capabilities Brought Together in One System
Date:9/21/2013

ATLANTA, Sept. 21, 2013 /PRNewswire/ – Elekta today announced Monaco® 5.0, which consolidates support for all of the most clinically useful delivery techniques in a single treatment planning system, and features refinements to planning speed and precision.

"This latest Monaco release brings together the best capabilities of Elekta's treatment planning portfolio into a single planning system to achieve a greater level of convenience and clinical versatility for the radiation oncology team," says Todd Powell, Executive Vice President of Elekta Software. "And, with a new system architecture, sophisticated treatment plans can now be developed with speeds often not attainable with previous planning systems."

Uniquely relying on an advanced Monte Carlo dose engine – considered the gold standard for calculating delivered radiation – Monaco is now a truly comprehensive treatment planning system, supporting the full breadth of radiation therapy techniques, including VMAT, IMRT, and 3D conformal radiation therapy. The system is exceptionally equipped for advanced stereotactic therapies, such as SRS and SRT, with added planning support for specialized beam shaping devices, including circular cones. 

"Developing treatment plans can be a resource-intensive task that limits a clinic's productivity and throughput," says Richard Stark, Senior Vice President of Elekta Software. "With a reinvented workflow and user interface, Monaco 5.0 is designed to simplify and accelerate the radiotherapy planning process. Combining these capabilities with a new system architecture based on CPU [central processor unit] and GPU-based [graphics processor unit] technology, Monaco sets a new standard in accuracy and speed."

Learn more at www.elekta.com/Monaco.

3D conformal radiation therapy, stereotactic cone and GPU-based architecture are pending FDA 510(k) clearance.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Elekta Radiation Therapy Technology Takes Weeks Off of Lung Cancer Treatments
2. Switzerlands Hopital Riviera Improves Confidence in Patient Treatment with Elektas Identify Solution
3. Elekta to Spotlight Versa HD System at 2013 ASTRO Annual Meeting
4. Elekta Introduces Groundbreaking Image Guidance Capabilities Integrated with Versa HD Cancer Treatment System
5. Johns Hopkins Kimmel Cancer Center Acquires Elekta Versa HD System
6. Elektas Leksell Gamma Knife Perfexion and Elekta Infinity Place First and Second in 2013 KLAS Radiation Therapy Report
7. Elekta to Exhibit New Versa HD Radiotherapy System at Annual Radiation Physics Conference
8. Odense Universitetshospital tilfører kræftpatienters stereotaktiske strålebehandling næsten tre gange hurtigere med Elektas Versa HD-system
9. Elekta Receives CE Marking for Clarity 4D Monitoring
10. Froedtert & The Medical College of Wisconsin Clinical Cancer Center Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
11. Elektas Leksell Gamma Knife Perfexion Earns Top Rank in 2013s Best in KLAS for Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):